29 results about "Human respiratory virus" patented technology

The invention provides a polypeptide, and the sequence of the polypeptide is AEDVGDVAFVKNDT. The polypeptide provided by the invention can inhibit the human respiratory syncytial virus surface protein F so as to inhibit the fusion of the human respiratory syncytial virus surface protein F and a host cell membrane. The invention also provides the sheep colostrum. The sheep colostrum comprises the polypeptide with the antiviral function, so that the sheep colostrum is helpful for old people with relatively weak resistance to resist infection of human respiratory syncytial viruses and promotes repair of respiratory mucosa. The invention also provides a preparation method of the sheep colostrum. The preparation method is simple and can be used for industrial production. The invention also provides a preparation method of the polypeptide.

The invention belongs to the technical field of medicines, and discloses a common goldenrop decoction active ingredient composition and application thereof in prevention and treatment of human respiratory syncytial virus. The invention relates to application of an active ingredient composition (isoliquiritigenin, baicalein, 6-shogaol, schisandrin B, ferulic acid and methyl salicylate) of Xiaochaihu decoction and / or a derivative of the active ingredient or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating RSV (Respiratory Syndrome Virus) infectious diseases. According to the invention, by establishing a mouse RSV infection model, the effect and the action mechanism of the composition in preventing and treating RSV infection are evaluated. Results show that each dose group can inhibit replication of RSV in mouse lung tissues, relieve pulmonary edema, improve pathological changes of the lung, inhibit expression of inflammatory factors and improve humoral immunity, and the effect is equivalent to that of ribavirin. The radix bupleuri granules have better effects on relieving pulmonary edema and inhibiting virus proliferation compared with small radix bupleuri granules. The composition of the effective components of the common goldenrop can provide a new drug treatment scheme for clinical RSV infectious diseases.

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

This invention discloses the application of 2,4-di-tert-butylphenol in the preparation of anti-human respiratory syncytial virus (RSV) drugs, belonging to the field of biomedical technology. 2,4-Di-tert-butylphenol exhibits good anti-RSV effects both in vitro and in vivo. In vitro, it can inhibit viral infection of cells, and in vivo, it can alleviate lung damage caused by viral infection and reduce lung inflammation. This invention provides experimental evidence for the development of highly effective and safe anti-RSV drugs and also offers more drug options for their development.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, which inhibit human respiratory syncytial virus (HRSV) or human metapneumovirus (HMPV). The present invention further relates to pharmaceutical compositions comprising the above-mentioned compounds for administration to a subject suffering from HRSV or HMPV infection. The present invention also relates to methods of treating a subject for HRSV or HMPV infection by administering a pharmaceutical composition comprising a compound of the present invention.

The invention relates to a human respiratory syncytial virus (hRSV) fusion F protein variant, a vaccine based on the human respiratory syncytial virus fusion F protein variant and application of the human respiratory syncytial virus fusion F protein variant. The hRSV fusion F protein variant (especially an mRNA vaccine based on the hRSV fusion F protein variant) can induce an organism to generate a high-level neutralizing antibody aiming at the respiratory syncytial virus, meanwhile, cellular immune response can be activated, dual activation of humoral immunity and cellular immunity is achieved, and the hRSV fusion F protein variant has cross protection efficacy on all subtypes of the hRSV. Therefore, a vaccine product based on the hRSV fusion F protein variant has important application value in clinical treatment and prevention and control of the respiratory syncytial virus.

The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

The present disclosure relates to the technical field of gene drugs, and particularly relates to an immunological composition containing a human respiratory syncytial virus antigen, wherein the human respiratory syncytial virus (hRSV) antigen is a pre-fusion hRSV F protein.

The present disclosure relates to an immune composition comprising or encoding a human respiratory syncytial virus antigen, selected from the group consisting of a nucleic acid immune composition, a polypeptide immune composition or a viral immune composition.

The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

The invention discloses a polypeptide inhibitor capable of effectively resisting respiratory tract RNA (Ribonucleic Acid) virus and application thereof. The TP series polypeptide provided by the invention has efficient and broad-spectrum antiviral activity. Therefore, a new strategy is provided for prevention and control of human respiratory viruses, and meanwhile, a new theoretical basis is provided for accelerating research and development of polypeptide small molecule drugs for resisting the respiratory viruses. The TP series polypeptide has a clear antiviral mechanism, can ensure the safety of application and the definition of an optimization approach, is convenient for later further development, improves the stability of a polypeptide drug, improves the administration mode of the polypeptide drug, and is expected to further expand the application range and effect of a polypeptide inhibitor in resisting respiratory tract RNA viruses.

The present disclosure provides compositions comprising at least two messenger RNAs (mRNA) consisting of a human respiratory syncytial virus (hRSV or RSV) F protein antigen, a human metapneumovirus (hMPV) F protein antigen, and / or a human parainfluenza virus 3 (hPIV3 or PIV3) F protein antigen; and methods of eliciting an immune response by administering the composition.

Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I:wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.

The present invention relates to formula (I): [Formula 1] JPEG2026513827000477.jpg3557 The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof that (I) inhibit inhibitors of human respiratory syncytial virus (HRSV) or human metapneumovirus (HMPV). The present invention further relates to a pharmaceutical composition comprising the above-mentioned compounds for administration to a subject suffering from HRSV or HMPV infection. The present invention also relates to a method for treating HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present application relates to a human respiratory syncytial virus (hRSV) fusion F protein variant, a vaccine based thereon and applications thereof. The hRSV fusion F protein variant of the present application (in particular the mRNA vaccine based thereon) can induce the body to produce high levels of neutralizing antibodies against respiratory syncytial virus, while being capable of activating cellular immune response, achieving dual activation of humoral immunity and cellular immunity, and having cross-protection efficacy against each subtype of hRSV. Therefore, the vaccine product based on the hRSV fusion F protein variant of the present application has important application value in the clinical treatment and prevention and control of respiratory syncytial virus.

The first subject of the invention is a set of primers for amplifying the nucleotide sequence of the RSVA N gene. The second subject of the invention is a set of primers for amplifying the nucleotide sequence of the RSVB N gene. The third subject of the invention is a method for detecting RSVA and RSVB. Another subject of the invention is a method for detecting an infection caused by RSVA or RSVB. The fifth subject of the invention is a kit for detecting an infection caused by RSVA or RSVB.

The embodiment of the application discloses a method for constructing a human respiratory syncytial virus newborn mouse infection model and application thereof.The method comprises the following steps: inoculating a virus liquid containing a human respiratory syncytial virus (RSV) into a 3-day-old SPF healthy BALB / c newborn mouse through nasal drops, and obtaining the human respiratory syncytial virus newborn mouse infection model after 4-5 days.The application successfully establishes a newborn mouse infection model which is simple to operate, good in repeatability and closer to clinical pathological characteristics.The model has the advantages of high virus infection rate, high similarity of pathological characteristics to human newborn infection, simple model construction method, short cycle, low cost, good stability and strong repeatability, and has a wide application prospect in RSV related research and development.

The application discloses a method for constructing a mouse severe pneumonia animal model infected by human respiratory syncytial virus and application, and relates to the technical field of viral pneumonia animal models. The method comprises the following steps: inoculating human respiratory syncytial virus on humanized IGF1R transgenic BALB / c mice, causing intra-pulmonary infection of bronchioles and / or lung tissues of the humanized IGF1R transgenic BALB / c mice, and obtaining the mouse severe pneumonia animal model infected by human respiratory syncytial virus. The method makes the mice more susceptible to human respiratory syncytial virus, and solves the problems that a conventional BALB / c mouse model cannot reproduce most of the human disease courses and generate high-titer virus proliferation, and cannot cause severe clinical symptoms due to semi-containment infection of inbred mice to human respiratory syncytial virus.

The invention belongs to the technical field of medicines, and discloses application of fumaric acid protoicellamate in preparation of medicines for preventing and treating respiratory virus infectious diseases. The invention particularly relates to application of a natural product fumaric acid protoicellamate or a metabolite thereof in vivo as an active ingredient in preparation of drugs with broad-spectrum antiviral activity and prevention and treatment of virus infectious diseases. The invention also discloses a medicine taking the trans-butene protoicellamate or the analogue thereof as an active ingredient. The traditional Chinese medicine composition can be used for preventing and treating respiratory virus infection such as human respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human rhinovirus (HRV), influenza virus, coronavirus, parainfluenza virus, measles virus, parotitis virus, rubella virus, adenovirus, cytomegalovirus, enterovirus, herpes simplex virus, varicella-zoster virus and the like; and infection of enteroviruses such as coxsackie virus, echovirus and the like can be prevented and treated, and a new drug treatment scheme is provided for clinical viral infection.

The present invention discloses an antibody, biological product, nucleic acid molecule, vector, and application thereof against RSV F protein, and relates to the field of immunoassay technology. The antibody against human respiratory syncytial virus F protein provided by the present invention has high specificity and high affinity characteristics and can be used to develop corresponding biological products, such as reagents, kits, test strips, antibody chips, antibody probes, etc., in particular products for respiratory syncytial virus detection. The antibody provided by the present invention can be used in various detection methods such as ELISA detection, immunochemiluminescence detection, and immunofluorescence detection, and has the advantages of a wide range of applications and strong applicability.

The present invention discloses compound of Formula (I), and ester, or prodrug thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV). The present invention further relates to pharmaceutical composition comprising the aforementioned compound for administration to a subject suffering from HRSV or HMPV infection.

The present disclosure provides a combined vaccine against human respiratory syncytial virus (RSV) infection and a method thereof for inducing immune response. The combined vaccine includes: a first composition including an immunologically effective dosage of a replication-deficient human adenovirus type 26 vector contains a nucleotide encoding an antigenic protein of RSV and a pharmaceutically acceptable vector; and a second composition including an immunologically effective dosage of a replication-deficient chimpanzee adenovirus type 63 vector contains a nucleotide encoding an antigenic protein of RSV and a pharmaceutically acceptable vector. The first composition is a primary immunization composition and the second composition is a booster immunization composition; or vice versa. In the present disclosure, the combined vaccine is used for inducing a protective immunity against RSV infection, and a method is provided for generating the protective immunity against RSV infection.

Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt, ester, or prodrug thereof: which inhibit human respiratory syncytial virus (HRSV) or are inhibitors of human metapneumovirus (HMPV). The invention also relates to a pharmaceutical composition containing the compound, and the pharmaceutical composition is applied to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising a compound of the invention.

The invention discloses a divalent human respiratory syncytial virus mRNA (messenger Ribonucleic Acid) and a divalent human respiratory syncytial virus mRNA vaccine containing the same. The invention provides divalent human respiratory syncytial virus mRNA containing mRNA for coding RSV A2 protein or fragment thereof and mRNA for coding RSV B1 protein or fragment thereof by screening antigen protein and optimizing mRNA structure and sequence. The mRNA vaccine prepared by the method can generate high-level specific antibodies and neutralizing antibodies at a lower dosage, effectively controls the amplification of RSV viruses in lungs, and has a very good cross protection effect; wherein the amino acid sequence of the RSV A2 protein or the fragment thereof is shown as any one of SEQ ID NO: 1-5, and the amino acid sequence of the RSV B1 protein or the fragment thereof is shown as any one of SEQ ID NO: 6-10.